Business Wire

FSP For Surface Protection Ltd Heading Towards Carbon-Neutral Surface Treatment - First in the World

Share

FSP For Surface Protection Ltd, an international provider of industrial surface treatment solutions, has set an environmental goal to be carbon neutral in its own production by the end of 2023. This is a tough target. However, FSP took up the challenge, reportedly becoming the first surface treatment company in the world to do so.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005781/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quality control in Stargard. Photo: FSP For Surface Protection Oy.

To achieve carbon neutrality, FSP analysed the carbon emissions of its surface treatment plants on a unit-by-unit basis for 2021. The analysis took into account the energy consumption of production processes, machinery and equipment. Emissions from premises and vehicles were also analysed. According to the study, the carbon footprint of the FSP (GHG Protocol, scope 1-2) in 2021 was 6 430 tonnes of carbon dioxide equivalent (t CO2e).

The contributions varied from country to country, but the main sources of emissions from total activities were electricity consumption (63%) and stationary combustion (29%). The challenge is that the company has production sites in several countries and operates them as part of customers' processes, so the ability to influence emissions is not always straightforward.

However, the company's commitment to the target is made easier by the fact that it has been working for a long time to reduce its carbon footprint, for example through material selection, optimisation of production processes and electricity consumption. The company is also working with customers and paint manufacturers to develop paints that meet both durability and environmental challenges even better.

To achieve carbon neutrality by the target date, the company will compensate its remaining emissions with certified emission reductions.

– A large number of our customers have set carbon reduction targets for their operations and many of them are aiming for carbon neutrality. Our work supports their targets and at the same time acts as our own market leader," says Jarno Huttunen, CEO of FSP.

FSP For Surface Protection Ltd is one of Europe's leading industrial surface treatment companies. The company employs more than 300 professionals in Europe. In 2022, FSP will have a turnover of around €26 M.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jarno Huttunen, CEO
FSP For Surface Protection Oy
+358 50 400 2082
jarno.huttunen@fspcorp.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 11:00:00 CEST | Press release

On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005495/en/ Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in

10 th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 08:15:00 CEST | Press release

Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit

Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 08:00:00 CEST | Press release

Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d

PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 07:22:00 CEST | Press release

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP

AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 04:00:00 CEST | Press release

With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA,PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom